niacinamide has been researched along with Neoplasms, Vascular in 1 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors tested sorafenib at a dose of 400 mg twice daily in patients with advanced vascular sarcoma (VS), high-grade liposarcomas, and leiomyosarcomas who had received 0 or 1 previous regimens for advanced disease." | 9.16 | Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. ( Borden, E; Bramwell, V; Demetri, GD; Goldblum, JR; Rankin, C; Ryan, CW; von Mehren, M, 2012) |
| "The authors tested sorafenib at a dose of 400 mg twice daily in patients with advanced vascular sarcoma (VS), high-grade liposarcomas, and leiomyosarcomas who had received 0 or 1 previous regimens for advanced disease." | 5.16 | Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. ( Borden, E; Bramwell, V; Demetri, GD; Goldblum, JR; Rankin, C; Ryan, CW; von Mehren, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| von Mehren, M | 1 |
| Rankin, C | 1 |
| Goldblum, JR | 1 |
| Demetri, GD | 1 |
| Bramwell, V | 1 |
| Ryan, CW | 1 |
| Borden, E | 1 |
1 trial available for niacinamide and Neoplasms, Vascular
| Article | Year |
|---|---|
Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Leiomyosar | 2012 |